ADAPYAdaptimmune Therapeutics PLC同业对比
Adaptimmune Therapeutics PLC 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADAPY本股 | — | — | — | — | 195.3%#1 | 37.8%#6 | -38.6%#4 | — | — | — | — | — |
| ABOS | $154M#9 | — | 1.8x#2 | — | — | -18.6%#10 | — | -138.7%#6 | -185.6%#3 | — | 31.1%#2 | — |
| ABPO | — | — | — | — | 50.0%#3 | 218.1%#1 | -4618.6%#8 | — | — | — | — | — |
| ABPWW | $116152#12 | 0.0x#1 | — | 0.6x#1 | 50.0%#3 | 218.1%#1 | -4618.6%#8 | — | — | — | -45.6%#7 | — |
| ACOG | $172M#7 | — | 3.0x#4 | 16.9x#6 | — | -39.8%#13 | -221.7%#5 | -36.0%#3 | — | — | -20.5%#6 | — |
| ADMA | $1.9B#2 | 12.2x#3 | 4.9x#5 | 3.8x#3 | 19.6%#5 | -25.7%#12 | 37.5%#1 | 37.6%#1 | 34.3%#1 | 5#1 | -52.2%#8 | — |
| ADPT | $3.6B#1 | — | 16.5x#7 | 12.9x#5 | 54.8%#2 | 62.7%#5 | -20.6%#3 | -27.5%#2 | -21.2%#2 | — | 108.8%#1 | — |
| AGEN | $249M#6 | 2.9x#2 | — | 2.2x#2 | 10.4%#6 | 98.7%#3 | -17.7%#2 | — | — | — | -1.1%#4 | — |
| AGMB | $433M#5 | — | — | — | — | — | — | — | — | — | — | — |
| AGTX | — | — | — | — | -100.0%#10 | 14.4%#9 | — | — | — | — | — | — |
| AIM | $4M#11 | — | 1.7x#1 | 41.4x#7 | -48.2%#8 | 19.4%#8 | -13254.5%#10 | -656.8%#7 | — | — | -97.0%#12 | — |
| ALEC | $164M#8 | — | 15.8x#6 | 7.8x#4 | -79.1%#9 | -20.2%#11 | -741.3%#6 | -1377.4%#8 | — | — | -17.8%#5 | — |
| ALGS | — | — | — | — | -39.5%#7 | 81.6%#4 | -4024.9%#7 | -76.1%#5 | — | — | -54.5%#9 | — |
| ALLO | $602M#4 | — | 2.2x#3 | — | -100.0%#10 | 25.9%#7 | — | -68.4%#4 | — | — | 15.6%#3 | — |
| ALVO | $950M#3 | — | — | — | — | — | — | — | — | — | -66.8%#10 | — |
| ALVOW | $100M#10 | — | — | — | — | — | — | — | — | — | -83.6%#11 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-07-25。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议